Peroxisome proliferator-activated receptor ␥ coactivator-1 (PGC-1) is a tissue-specific coactivator that enhances the activity of many nuclear receptors and coordinates transcriptional programs important for energy metabolism. We describe here a novel PGC-1-related coactivator that is expressed in a similar tissue-specific manner as PGC-1, with the highest levels in heart and skeletal muscle. In contrast to PGC-1, the new coactivator shows high receptor specificity. It enhances potently the activity of estrogen receptor (ER) ␣, while having only small effects on other receptors. Because of its nuclear receptor selectivity, we have termed the new protein PERC (PGC-1 related Estrogen Receptor Coactivator). We show here that the coactivation function of PERC relies on a bipartite transcriptional activation domain and two LXXLL motifs that interact with the AF2 domain of ER␣ in an estrogen-dependent manner. PERC and PGC-1 are likely to have different functions in ER signaling. Whereas PERC acts selectively on ER␣ and not on the second estrogen receptor ER, PGC-1 coactivates strongly both ERs. Moreover, PERC and PGC-1 show distinct preferences for enhancing ER␣ in different promoter contexts. Finally, PERC enhances the ER␣-mediated response to the partial agonist tamoxifen, while PGC-1 modestly represses it. The two coactivators are likely to mediate distinct, tissue-specific responses to estrogens.Nuclear receptors are ligand-regulated transcription factors with a broad range of functions in development, physiology, and behavior. They include steroid hormone receptors for glucocorticoids, mineralocorticoids, progestins, estrogens, and androgens, as well as receptors for thyroid hormone, retinoids, vitamin D, and intermediary metabolites (1). They use a conserved DNA binding domain (DBD) 1 to interact with specific sites in the genome, termed hormone response elements (HREs). DNA-bound receptors can activate the expression of genes in the vicinity of HREs, via two transcriptional activation functions, denoted AF1 and AF2. AF1 lies in the N-terminal part of the receptors and varies significantly from one receptor to another. AF2 is located at the conserved ligand binding domain (LBD) and relies on an agonist ligand-induced protein conformation (2-5). Depending on cellular and promoter context, AF1 and AF2 act independently or synergistically to regulate gene expression. A large number of proteins that interact with the AF2 domain and enhance the activity of nuclear receptors have been identified (reviewed in Refs. 6 -8). They include the three members of the p160 steroid receptor coactivator (SRC) family (SRC-1/NcoA-1, TIF2/GRIP1/NcoA-2, AIB1/pCIP/ACTR/RAC3/ SRC-3), the cointegrators CBP and p300, components of the Mediator complex, individual coactivators such as PGC-1, NRIF3, ASC-2/RAP250, PELP1, and CAPER, and the family of CITED proteins (6 -12). Most of these coactivators harbor one or multiple LXXLL motifs (L being leucine and X any amino acid) within short amphipathic helices (13,14). These LXXLL motifs, als...